PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Title only   |   Print    Next page > 
     
Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment
FDA IND Clearance for CBL-0201WR —Caliway has cleared its Investigational New Drug application for CBL-0201WR, a Phase 2 trial evaluating CBL-514 in combination with tirzepatide. U.S. IRB Approval ...
2026-08-26T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
HaemaLogiX Announces Major Milestone with First Patient Successfully Dosed with KMCAR™ T-Cell
KEY POINTS ...
2026-08-26T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Metabolon Completes Landmark Global Health Pilot Advancing Women's and Infant Health
Innovative sample collection methods developed through Gates Foundation-funded grant enable high-quality metabolomics biomarker discovery in populations from low- and middle-income countries ...
2026-08-25T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
WuXi Biologics Reports Strong Profitable Growth in H1 2026
Revenue of RMB 11.8 billion grew 18.4% YoY (23.4% YoY in USD) IFRS gross profit margin expanded to 46.2% (+350 bps YoY) and adjusted gross profit margin expanded to 48.4% (+280 bps YoY), despite foreign ...
2026-08-25T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Fosun Pharma Announces 2026 Interim Results
Globalization Accelerates Value Realization of Innovative Drugs ...
2026-08-25T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Innovent Announces 2026 Interim Results and Business Updates
Transforming from Regional Leader to Global Premier: ...
2026-08-25T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners
BEIJING , Aug. 25, 2026 /PRNewswire/ -- On August 25, Haisco Pharmaceutical Group Co., Ltd. ("Haisco") (Ticker Code: 002653) announced that it has entered into an exclusive licensing ...
2026-08-25T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Cambrex High Point Completes FDA, PMDA and TGA Pre-Approval Inspections, Advancing Commercial Manufacturing Capabilities
EAST RUTHERFORD, N.J. , Aug. 25, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the successful completion of three Pre-Approval ...
2026-08-25T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Senhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR Expected in Q1 2027
TAIPEI , Aug. 25, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy ...
2026-08-25T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Classys Nears 50,000 Devices Sold Globally as Full-Lineup Growth Accelerates
Expands global portfolio beyond HIFU and MRF to include MNRF, laser, and dermabrasion devices, strengthening its medium- to long-term growth foundation 1H26 Exports, excluding shipments to its ...
2026-08-25T    Cosmetics & Personal Care   Medical Equipment   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.